Other
Accounts Receivable, Allowance for Credit Loss
Moderna Accounts Receivable, Allowance for Credit Loss increased by 100.0% to $6.00M in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ4 2024
Last reportedQ1 2026May 1, 2026
How to read this metric
An increasing allowance relative to receivables may signal deteriorating credit quality among clients.
Detailed definition
This is a contra-asset account representing the estimated amount of accounts receivable that the company does not expect...
Peer comparison
Standard across service industries; levels are compared against historical write-off rates.
Metric ID:
other_allowance_for_doubtful_accounts_receivableHistorical Data
5 periods
| Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $0.00 | $12.00M | $3.00M | $3.00M | $6.00M |
| QoQ Change | — | — | -75.0% | +0.0% | +100.0% |
Range$0.00 – $12.00M
Current Streak2 quarters growth
Accounts Receivable, Allowance for Credit Loss at Other Companies
Frequently Asked Questions
- What is Moderna's accounts receivable, allowance for credit loss?
- Moderna (MRNA) reported accounts receivable, allowance for credit loss of $6.00M in Q1 2026.
- What does accounts receivable, allowance for credit loss mean?
- The estimated portion of customer invoices that will likely go unpaid.